View Author
patient cancer irinotecan tumor melanoma survival blood lesion treatment study tissue factor oncol clearance disease cyp 3a parameter perfusion stage analysis midazolam lymph limb perfusion response breslow thickness signi melphalan mucosa erythromycin breath test table pharmacokinetic prognostic sentinel value erythromycin month tumor necrosis factor minute oxygenation volume in-transit toxicity procedure thickness breslow midazolam clearance breath cancer institute number prognostic factors ulceration -38 metastasi sn-positive spectroscopy verweij j tnf-based sn-positive patients metastase sn status sn -38g midazolam clearance test necrosis hypoxia effect carcinoma variant progression metabolism status probe signi ficantly irinotecan clearance tnf-based ilp difference cyp 3a phenotype fication prognostic value iiiab sn -38
4 Most Recent Publications
|
High positive sentinel node identification rate by EORTC melanoma group protocol
(Article)
Akkooi, A.C.J. van Wilt, J.H.W. de Verhoef, C. Graveland, W.J. Geel, A.N. van Kliffen, M. |
2006-02-01
|
|
Measurement of hypoxia-related parameters in bronchial mucosa by use of optical spectroscopy.
(Article)
Bard, M.P.L. Amelink, A. Hegt, V.N. Graveland, W.J. Sterenborg, H.J.C.M. Hoogsteden, H.C. Aerts, J.G.J.V. |
2005-05-15
|
|
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
(Article)
Mathijssen, R.H.J. Jong, F.A. de Sparreboom, A. Schaik, R.H.N. van Lepper, E.R. Friberg, L.E. Rietveld, T. Bruijn, P. de Graveland, W.J. Figg, W.D. Verweij, J. |
2004-11-03
|
|
One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases
(Article)
Grunhagen, D.J. Brunstein, F. Graveland, W.J. Geel, A.N. van Wilt, J.H.W. de Eggermont, A.M.M. |
2004-01-01
|
